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Pregnancy riskAims: The effectiveness of physical activity (PA) programs for prevention of gestational dia-
betes (GDM) lacks conclusive evidence. The aim of this study was to generate clear evi-
dence regarding the effectiveness of physical activity programs in GDM prevention to
guide clinical practice.
Methods: PubMed/Medline, ISI Web of Science, Scopus, and EMBASE were searched to iden-
tify the randomized trials (RCTs) published until June 2019. Randomised controlled trials
enrolling women at high risk before the 20th week of gestation comparing the effect of
PA interventions with usual care for prevention of GDM were retrieved. Data obtained were
synthesised using a bias-adjusted model of meta-analysis.
Results: A total of 1467 adult women in 11 eligible trials were included. The risk of GDM was
significantly lower with PA, but only when it was delivered in the healthcare facility (RR
0.53; 95% CI 0.38–0.74). The number needed to treat with PA in pregnancy (compared to
usual care) to prevent one GDM event was 18 (95% CI 14 – 29). The overall effect of PA inter-
ventions regardless of location of the intervention was RR 0.69 (95% CI 0.51 – 0.94).
Conclusions: This study provides evidence that in-facility physical activity programs started
before the 20th week of gestation can significantly decrease the incidence of GDM among
women at high risk.
 2020 Elsevier B.V. All rights reserved.1. Introduction
With the current obesity epidemic, gestational diabetes melli-
tus (GDM) has also been on the rise given that the key risk fac-tor is maternal adiposity [1]. GDM is also associated with
women of an advanced age at pregnancy, having a family his-
tory of diabetes or a past history of GDM or macrosomia [2-5].
Development of GDM has implications for both the mothersity, Doha,
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 7 1(e.g. interventions to manage hyperglycemia) and the baby
(e.g. birth complications or longer-term dysmetabolic traits
in the child) [6].
Preventing GDM is a priority in pregnancy. Several inter-
ventions to mitigate hyperglycemia and avoid birth complica-
tions (e.g. macrosomia) have been suggested, the main ones
being pharmacological, physical activity and lifestyle coun-
selling [7]. Results with metformin have been disappointing,
with the latest synthesis of randomised controlled trials
(RCT’s) conclusively demonstrating a lack of efficacy in pre-
venting GDM [8]. Nutrition counseling, diets, physical activity
(PA) programs and PA counselling have also been extensively
trialed in pregnancy. The rationale for the latter is that GDM is
linked to insulin resistance on a backdrop of beta-cell dys-
function [9] and such interventionsmodulate insulin sensitiv-
ity due to their possible effect on gestational weight gain [7].
Evidence has been generated since 2002, when the first RCT
of counseling (nutrition and/or physical activity) in a high risk
population was attempted [10]. Nonetheless, recent multicen-
tre RCTs including the LIMIT [11], UK Pregnancies Better Eat-
ing and Activity (UPBEAT) [12], Finnish Gestational Diabetes
Prevention (RADIEL) [13] and the Vitamin D and Lifestyle
Intervention (DALI) [14] trials that evaluated the effect of
counselling among pregnant women at high risk have all
been disappointing in terms of GDM prevention. What is
unclear is if direct PA programs as the intervention (as
opposed to counselling) can make a difference.
There have also been many attempts to synthesize the
available evidence examining the potential role of counselling
or PA programs on GDM prevention in high risk populations
[15]. In terms of more recent studies, we were able to identify
eight (references in supplementary material B) syntheses
published during the period between 2012 and 2019 but they
all mix up counselling and PA program interventions and thus
despite the volume of syntheses, this area remains inconclu-
sive and had a number of methodological issues. For example
a 2019 meta-analysis reported findings that are not plausible
since they report that nutrition or PA counselling given alone
had a significant effect but not the combination of nutrition
and PA counselling [16]. They also mix up counselling with
PA programs as well as of studies of women at high and low
risk and this added to the contradictory results. In addition
they included activities like Yoga [17] which is a lower inten-
sity exercise program compared to resistance training. Insuf-
ficient consideration of the target population (women at high
risk) and type of intervention (counseling vs PA programs)
results in an inappropriate classification of studies. The most
recent synthesis of experimental studies published in 2019
[18] included 10 RCTs related to the nutrition counselling
and exercise intervention of which two were not deemed
appropriate to be included [14,19] and three other studies that
satisfy the inclusion criteria were not included [20-22]. The
authors Inappropriately use a network meta-analysis
approach which is not ideal as it is unlikely that any patient
in the network could have been given any of the treatments
in the network (metformin. probiotics, exercise, vitamin D).
As such, the indirect comparisons are not protected by ran-
domisation and are more likely to be confounded by differ-
ences between the trials. Similarly, the third 2019 meta-
analysis [23] included only five out of eleven potentially rele-vant trials on exercise and thus did not satisfy the inclusion
criteria. Thus, despite the proliferation of both RCTs and
meta-analyses, the question regarding the efficacy of these
PA program interventions remains unresolved and further tri-
als are being planned (such as the PLEDGE trial in Qatar;
NPRP10-0213-170456).
Our clinical question for this study is the efficacy of PA
intervention programs in women at high risk delivered in
pregnancy for GDM prevention. We were commissioned to
undertake this synthesis and bring together specialists in rel-
evant areas, our aim being to provide some closure on the




Several databases were searched (PubMed, Embase, Cochrane
Central Register of Controlled Trials, Cochrane library, Clini-
calTrials.gov, WHO website, PsycINFO, and the grey literature
(www.opengrey.eu/)). We deliberately conducted a broad
search using keywords and synonyms to achieve good cover-
age. Thiswas followed by amanual search of the top 50 similar
citations (PubMed) on studies that were finally included after
full text review. Simple structured Boolean searches were also
conducted to assess the completeness of our RCT evidence
base [24]. A final hand search of references from the selected
studies and relevant syntheses was then done to ensure that
no relevant RCTs were missed. We report our search strategy
in details in supplementary material, section A.2.2. Study selection
We restricted inclusions to human studies after 1966 and till
June 2020. Further restrictions were the English language.
Selection was also restricted to the RCT design that included
the interventions of interest delivered from early pregnancy)
as information on incident GDM during pregnancy. Exclusions
were made for studies that included low GDM risk partici-
pants, had participants with pre-existing diabetes or GDM
diagnosed at entry, or were not carried out in routine care set-
tings. Studieswere considered to have recruited high-risk par-
ticipants if they had any of the following:
(a) overweight or obesity
(b) prior GDM or macrosomia
(c) high risk status on a GDM risk assessment tool [25].
No exclusions were made based on diagnosis of GDM
according to different international definitions [26-32]
We excluded trials that did not report PA intervention pro-
grams, did not compare the intervention with the usual stan-
dard of care, were not RCTs or where GDM was not an
outcome (primary or secondary). We also pre-specified exclu-
sion of low intensity PA programs such as Yoga andmeditation
exercises because there is evidence of dose response, with
higher exercise intensities producing greater benefits on insu-
lin sensitivity. All studies considered in this analysis excluded
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 7 1 3pre-existing diabetes and GDM diagnosed at entry. This syn-
thesis therefore includes incident GDM data assessed around
24–32 weeks of gestation in women without GDM at entry.
2.3. Data extraction and quality assessment
Independent screening of titles, abstracts and full texts by
two authors (OM, AM) was carried out. All final decisions were
discussed with a third author (SD) when there were contro-
versies and resolved through discussion. A similar approach
was used for risk of bias assessment or when data was
extracted (e.g. numbers of events). When studies did not
report important data or there was an inconsistency, we
emailed the corresponding authors. Only two arms were
extracted per study and in studies with three or more arms,
extraction of data was for the most relevant intervention
arm and the control arm. Some studies were reported strati-
fied by BMI which allowed us to include the high risk stratum
as these included women at high risk.
We applied the Cochrane Risk of Bias 2.0 tool.[33] for
assessment of the quality of the original studies and this
has six domains to be assessed (supplementary section D).
This tool is used to assess the studies against several bias
safeguards across six domains. The domains are then judged
at low or high risk of bias in each study and these were
counted (1 = high; 0 = low and 0.5 = uncertain). A previous
study has delineated how such counts may be used to create
a relative quality rank (relative to the best study in the meta-
analysis) which rescales these counts between 0 and 1 [34].
The latter rank was automatically computed by our software
and used for bias adjustment in the meta-analysis [35,36].
2.4. Data synthesis
The risk ratio (RR) was the effect size in this synthesis. Overall
and pre-specified subgroup analyses were undertaken. The
pre-specified subgroups were in-facility supervised exercise
or not, recruitment time (before 16 weeks gestation or up to
20 weeks), risk status (dichotomised into overweight/obesity
and other high risk criteria) and incidence of GDM in the con-
trol arms (<=20% versus > 20%). These were undertaken only
if thereweremore than twoRCTspergroup.We tested for inter-
actions by using a Q-test under fixed effect weights to assess
the dispersion of the respective summary effects about the
combined effect [37]. This is equivalent to using aQ-test to par-
tition the variance and test the between-subgroups portion of
the variance or use a Z-test to compare the two effect sizes
directly.
Meta-analysis utilised the quality effects model [35,36] as
it is more robust [38] than the classic fixed- or random-
effects models when analyzing heterogeneous studies. We
depicted the synthesized data using forest plots and sensitiv-
ity to model selection was tested by conducting the analysis
using two other models (the robust IVhet model [39] and the
conventional random effects model [40] and these are
reported in the supplementary material).
We checked for inconsistency using the I2 statistic [41] and
checked for possible small study effects through generation
of Doi plots and the LFK index [42]. These methods are more
reliable [42] than commonly used funnel plots or Egger’sregression [43]. Interpretation of these results followed previ-
ous guidelines [42]. Only exact P values were reported. All
analyses were conducted using Stata version 15 (College Sta-
tion, TX, USA) and the admetan package [44] and reporting
followed the PRISMA [45] guidelines.3. Results
3.1. Identified studies
A total of 1599 potentially relevant papers were found across
databases andwere sorted and accessed using EndNote X7. To
this we added additional searches as described in the meth-
ods section. After screening of titles and abstracts, and
removal of duplicates across the various databases, full texts
of 195 papers were retrieved. We excluded studies of specific
types of dietary supplements, weight monitoring, meditation
type exercises or that did not use usual care controls. Two
quasi-experimental trials using convenience sampling were
also excludedOther exclusions included women without high
risk status and trials with interventions that were nutrition /
PA counseling only. All references to exclude trials are given
in the supplementary material section B. In all, 11 RCT’s
(Table 1) finally met the inclusion criteria for this synthesis
[20-22,46-53]. The study selection process is depicted in Fig. 1.
3.2. Study characteristics
High risk was defined as obesity [46,50,53] or overweight/obe-
sity [22,47,48,51,52] or through the presence of one of several
risk factors in addition to or without overweight/obesity
[20,21,49] (including prior GDM, prior macrosomia, a risk tool
score or age > 35–40y). Interestingly, only the tool used a def-
inition of high risk that considered a family history of type 2
diabetes perhaps because it is not an independent predictor
of GDM [54]. While the criteria for high risk vary, they all lead
to women whose risk status is greater than the average
woman in pregnancy with none of the risk factors thus ensur-
ing that this study included women who were at higher than
average risk. All trials were single centre RCTs.
3.3. Origin of the studies
One RCT was from Asia [51], three were from Oceania
[20,46,52] three were from Europe [47,49,50] and four were
from North America [21,22,48,53].
3.4. Interventions
Of the 11 RCTs, five [22,47,49,51,53] utilised a health care facil-
ity based supervised exercise program while six
[20,21,46,48,50,52] were supervised outside of the health care
facility. The recruitment was reported to have been prior to
the 16th gestational week in seven [20,21,46,48,50,51,53] stud-
ies and up to 20 weeks in four [22,47,49,52] studies. Across the
RCTs, intervention continued till approximately 36 weeks and
all studies provided participants with pregnancy-specific diet-
ary advice as per local guidelines. Further details of these
interventions are given in supplementary material, section B.
Table 1 – Population characteristics of included studies.
Study (Year) Country Study setting, study period, and criteria for
inclusion
Criteria for high risk Study Design Sample size of women
at risk for GDM
Bisson (2015)[53] Canada Setting: Centre Hospitalier Universitaire (CHU) de
Québec and the Centre de santé et de services
sociaux de la Vieille-Capitale,
Period: (October 2011 to November 2013)
Criteria: Pregnant women  18 years old,
BM  30 kg/m2, presented a singleton pregnancy
and planned to deliver in participating hospitals.
BMI  30 kg/m2 RCT 48
BAMBINO Callaway (2010)[46] Australia Setting: Royal Brisbane and Women’s Hospital-
Australia
Period: -
Criteria: Obese pregnant women who were at
12 weeks of gestation.
Obesity Pilot RCT 50
ETIP
Garnæs (2016)[47]
Norway Setting: Trondheim University Hospital, in
Trondheim, Norway
Period: -
Participants: Pregnant women with BMI  28 kg/
m2, age  18 y, gestational week < 18, and carrying
one singleton live fetus.
BMI  28 kg/m2 RCT 74
Guelfi (2016)[20] Australia Setting: Clinics, obstetricians, general
practitioners, and ultrasound practices in Australia
Period: (June 2011 and Jul 2014)
Criteria: Pregnant women with a history of GDM in
a previous pregnancy and are < 14 weeks of
gestation, > 18 years, and able to participate in a
14-week exercise program.
Previous GDM RCT 169
Hui (2014)[22] Canada Setting: Prenatal classes or community clinics -
Winnipeg, Manitoba from
Period: (May 2009 and Dec 2011)
Criteria: Pregnant women < 20 weeks of pregnancy
without diabetes
Subgroup with BMI >= 25 RCT 56
Kong (2014)[48] USA Setting: Mass e-mail service provided by the Iowa
State University to the students, staff, and faculty
on campus, online advertisement (i.e., Craigslist),
and flyers posted throughout the community (i.e.,
restaurants, public libraries, and grocery stores)-
USA
Period: (-)
Criteria: Pregnant women age (18 – 45) yr with
singleton pregnancy, non-smoker and are self-
reported overweight (BMI  25.0 kg.m-2) or obese
(BMI  30.0 kg.m-2) before pregnancy. With no
prior history of chronic diseases, and no prior
history of GDM, engaged in less than three 30-min


















































Study (Year) Country Study setting, study period, and criteria for
inclusion
Criteria for high risk Study Design Sample size of women
at risk for GDM
Nobles (2015)[21] USA Setting: Ambulatory obstetrical practices of
Baystate Medical Center-USA
Period: (2007 to 2012)
Criteria: Women in their first trimester of
pregnancy, between the ages of 16 and 40, and at
increased risk for GDM
-BMI>=25
or Family history of diabetes
or prior GDM according to ADA
RCT 251
Oostdam (2012)[49] Netherland Setting: Hospitals and midwifery practices-
Netherland between
Period: (2007 to 2011).
Criteria: Pregnant women who were overweight or
obese and at risk for GDM,
- BMI>=25
Or History of macrosomia






Netherland Setting: Hvidovre Hospital, University of
Copenhage-Netherlands from
Period: (March 2009 to March 2012)
Criteria: Obese pregnant women with BMI  30 kg/
m2
BMI  30 kg/m2 RCT 259
Seneviratne (2016)[52] Setting: Home-based intervention, Auckland, New
Zealand
Period: (March 2013 and Oct 2014)
Criteria: Participants were women aged 18–
40 years, BMI  25 kg/m2 and a singleton
pregnancy < 20 weeks of gestation.
BMI  25 kg/m2 RCT 74
Wang (2017)[51] China Setting: Peking University First Hospital-China
Period: (Dec 2014 through July 2016)
Criteria: Nonsmoking women age > 18 years with a
singleton pregnancy who met the criteria for
overweight/obese status BMI (24–28 kg/m2) and
had an uncomplicated pregnancy at < 12 weeks















































Fig. 1 – Flowchart of the selection of studies.
6 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 7 13.5. Ascertainment of GDM status
Seven [20-22,46,47,51,52] studies used the 75 g glucose toler-
ance test (GTT) and four [48-50,53] RCTs did not report the
glucose dose used for GDM diagnosis. We did not contact
the authors to ascertain this information as it was unlikely
to impact on these results but was taken into account during
quality assessment. Seven GTT diagnostic thresholds were
used across studies (supplementary material, section C).
The usual timing of the GTTwas used and cut-off thresholds
are reported in supplementary materials, section C.3.6. GDM incidence
The control group incidence of GDM across the different
trials was assessed and ranged between 5 and 41%. Seven
[21,22,46,48-50,52] trials reported under 20% cumulative
incidence (5–15%) of GDM, two [47,53] reported 21–25%
GDM and the last two [20,51] reported 40–41% GDM.
The latter two studies had high GDM rates because they
either limited recruitment to women with prior GDM [20]
or had significant attrition [51] perhaps leading to selec-
tion bias.
Fig. 2 – Meta-analysis of eleven RCTs of PA program interventions in pregnancy with individual and summary risk ratio’s
indicated. Weights are from Doi’s quality effects model.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 7 1 73.7. Quality of the studies
The least deficient domains (across studies) were attrition,
analysis and randomization. The most deficient domain was
intervention adherence. Details of the quality assessment
for each study is depicted in supplementary material section
D. The relative ranks across the studies was between 0.5 and 1
for the 11 RCTs Details are given in supplementary material
section D.
3.8. Quantitative synthesis: Magnitude and precision of
overall effect
Across 11 trials and 1467 women, 722 received PA interven-
tions through pregnancy and 745 received usual care. GDM
developed in 100 PA treated women and in 148 usual careTable 2 – Results of pre-specified subgroup analyses.
Analysis and variable Studies (n) I2 Participants (NPA
In-facility exercise program
Yes 5 0% 309 + 318
No 6 0% 413 + 427
Incidence of GDM
<=20% 7 0% 444 + 467
>20% 4 63.6 278 + 278
Approximate start of trial
Before 16 weeks 7 28.4% 532 + 547
Up to 20 weeks 4 31.2% 190 + 198
Criterion for high risk
Other 3 0% 296 + 308
Overweight/Obese 8 8.5% 426 + 437controls (Fig. 2). PA reduced the risk of GDM compared with
usual care (RR 0.69, 95% CI 0.51 to 0.94; Fig. 2). The pooled
effect across in-facility exercise was RR 0.51 (95% CI 0.37
to 0.71; Fig. 2). Assuming the 12% median baseline risk of
GDM in women at high risk, this translates to one less
GDM occurrence for every 18 (95%CI 14–29) women under-
going an in-facility PA program in pregnancy compared
with usual care.
There was interaction by use of an in-facility exercise
venue (P = 0.015; Table 2). Sensitivity analysis replacing the
synthesis model with the IVhet model (RR 0.72; 95% CI 0.52
to 0.99) or with the random effects model (RR 0.70; 95% CI
0.52 to 0.95) produced similar results. The primary results
therefore are robust to the selection of the analytic approach
even though the three models assign different weights across
studies (supplementary material, section E).+ Ncon) Risk ratio (95% CI) Test for interaction p-value
0.51 (0.37 – 0.71) 0.015
0.92 (0.66 – 1.29)
0.74 (0.47 – 1.17) 0.736
0.65 (0.38 – 1.13)
0.71 (0.51 – 1.00) 0.756
0.62 (0.26 – 1.47)
0.87 (0.64 – 1.18) 0.111
0.57 (0.38 – 0.86)
8 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 8 ( 2 0 2 0 ) 1 0 8 3 7 13.9. Consistency, directness and publication bias
The patients, intervention tested and outcome examined
were similar to those of interest to clinicians and the health-
care system. Incident GDM in an index pregnancy is certainly
of interest to patients and care-givers. All comparisons were
head-to-head and these findings are directly of relevance.
Across the 11 RCTs the I2 was 0% within facility subgroups
and thus there was consistency of the effect seen. A cumula-
tive analysis (not shown) suggested that the Garnaes et al trial
in 2016, was the point at which there was significance of the
results and this was maintained thereafter as additional trials
were added on.
The 11 RCTs demonstrated no asymmetry overall of the
study effects (supplementary material, section F, left panel;
LFK index 0.14). This suggests the absence of small study
effects. The funnel plot (supplementary material, section F,
right panel) was not clearly interpretable, as expected [55]
while Egger’s P (P = 0.69) also suggested symmetry.
4. Discussion
This meta-analysis confirms, for the first time, that PA pro-
vided in-facility and started prior to the 16th–20th week of
gestation, can prevent emerging GDM in pregnant women at
high-risk. This finding was consistent across studies regard-
less of the different definitions of high risk patients or of
the timing of PA initiation.
GDM occurs when pancreatic beta-cells cannot cope with
the insulin resistance of pregnancy, and this could be multi-
factorial including impaired beta cell number, mass or func-
tion or a mixture of all these factors [9]. The impact on
beta-cells of PA interventions, like that of metformin, must
be largely compensatory (addressing insulin resistance) with
little opportunity for improvement in beta-cell function over
the short period of gestation. Insulin resistance increases
later in pregnancy [56], triggering glycaemic deterioration
and this is a reflection of pre-existing beta-cell compromise.
While the PA effect is sufficient to mitigate GDM related dys-
glycemia, perhaps by mitigating the increasing insulin resis-
tance expected as pregnancy proceeds, this appears not to
be the case with counseling interventions [11-14]. We know
that insulin resistance increases during gestation and this
increase is larger when GDM ensues [57] and thus PA must
have a mitigating effect here. This needs to be explored in
future studies.
This synthesis has several strengths over those previously
conducted. Eligibility criteria were explicit, the search was
very comprehensive and conducted by a specialist librarian,
risk of bias assessment was used for bias adjustment, and
there was an explicit consideration of reporting bias, sub-
group effects and reporting of the GRADE domains in relation
to the outcome [58]. A limitation of this study is that we did
not register it on PROSPERO although doing so may also have
disadvantages such as deterrence of others from similar
research that may be of higher quality and other issues raised
previously [59]. Another limitation is that we do not know
how much the control groups changed after the start of the
trials. Contamination of the control group is a real risk withthe sort of RCTs we included in this synthesis and could be
a factor in the seeming lack of efficacy of these interventions.
This would be more of a problem with counseling compared
to PA interventions. However there have been two cluster ran-
domised trials (FeLIPO [60] and GeliS [61]) that would have
avoided contamination yet demonstrated no efficacy for the
counseling intervention in terms of GDM prevention. Both
the latter trials included low risk women however. Another
limitation of this synthesis is the use of studies where the
diagnostic thresholds for GDM varied and we know that cer-
tain GTT thresholds yield more cases than others [62,63] This
is not a major problem given that comparisons are made
within trials and it is unlikely that the intervention modifies
the operating characteristics of the specific criterion used to
diagnose GDM. Finally, we did not conduct subgroups accord-
ing to BMI, history of prior GDM or macrosomia as these data
were not consistently reported across studies.
We conclude that these results should be brought to the
attention of clinicians so that they are aware that PA is of
benefit for GDM prevention. Clinicians now have data that
supports supervised exercise in pregnancy for the GDM pre-
vention indication. What may now be important for future
research is to compare PA in-facility versus outside the
health care facility to establish the determinants of its suc-
cess in GDM prevention. In addition, the possibilities for
these interventions are changing a lot with the wealth of
mobile and other apps and web pages coming up. Teleme-
dicine support from health centres needs a separate inves-
tigation as there might be an opening here that could be
more effective. The efficacy of the intervention must also
be looked at in the light of patient activation – a measure
of patient ‘‘quality”.
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